Reduction in Duration of Common Colds by Zinc Gluconate Lozenges in a Double-Blind Study

Antimicrob Agents Chemother. 1984 Jan;25(1):20-4. doi: 10.1128/aac.25.1.20.

Abstract

As a possible treatment for common colds, we tested zinc gluconate lozenges in a double-blind, placebo-controlled, clinical trial. One 23-mg zinc lozenge or matched placebo was dissolved in the mouth every 2 wakeful h after an initial double dose. After 7 days, 86% of 37 zinc-treated subjects were asymptomatic, compared with only 46% of 28 placebo-treated subjects (P = 0.0005). Side effects or complaints were usually minor and consisted mainly of objectionable taste and mouth irritation. Zinc lozenges shortened the average duration of common colds by about 7 days.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Child
  • Clinical Trials as Topic
  • Common Cold / drug therapy*
  • Double-Blind Method
  • Female
  • Gluconates / administration & dosage*
  • Gluconates / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Zinc / administration & dosage*
  • Zinc / adverse effects

Substances

  • Gluconates
  • Zinc
  • gluconic acid